Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design
Abstract Background Patients treated with drug-coated balloons (DCB) have the theoretical advantage of adopting a low-intensity antiplatelet regimen due to the absence of struts and polymers. Nevertheless, the optimal antiplatelet strategy for patients undergoing DCB-only treatment remains a topic o...
Main Authors: | Chao Gao, Bin Zhu, Jianzheng Liu, Zhiwei Jiang, Tao Hu, Qiong Wang, Yi Liu, Ming Yuan, Fei Li, Ruining Zhang, Jielai Xia, Yoshinobu Onuma, Duolao Wang, Patrick Serruys, Ling Tao, on behalf of the REC-CAGEFREE II Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12872-024-03709-1 |
Similar Items
-
Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial
by: Pascal Vranckx, et al.
Published: (2021-09-01) -
Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
by: Francesco Condello, et al.
Published: (2021-11-01) -
A life-threatening massive hemoptysis case in the course of dual antiplatelet therapy with ticagrelor
by: Dimitrios Molyvas, et al.
Published: (2022-09-01) -
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01) -
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial
by: Chao Gao, et al.
Published: (2020-10-01)